Biotechnology News

Forventningerne til omsætning og EBITDA-margin er opjusteret som følge af et stærkere salg i Travel Health end forventet. KØBENHAVN, Danmark, 8. oktober 2026 – Bavarian Nordic A/S (OMX: BAVA)...

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...

October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY...

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with...

The Botswana subsidiary expands Bio Usawa’s international presence, joining the company’s existing operations in Rwanda, Kenya, and Germany.

HIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for...

Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for...

Lyon (France), le 7 octobre 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’à la suite d’une nouvelle évaluation du rapport...

Company AnnouncementCOPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting.At the Extraordinary General Meeting the proposal from the...

Informations relatives au nombre total de droits de vote et d’actions composant le capital